Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with nab-paclitaxel plus capecitabine followed by sintilimab plus capecitabine maintenance in metastatic triple-negative breast cancer
ChiCTR2100054545Phase 2Recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel and capecitabine in triple-negative breast cancer (TNBC), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Target lesion. Started Jan 2022; status: recruiting.
02
Drugs
sintilimabpaclitaxelcapecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2100054545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054545.